Originally published by our sister publication Gastroenterology & Endoscopy News
VANCOUVER, B.C.—In patients with inflammatory bowel disease, neither biologics nor small molecule targeted therapies increase the risk for major adverse cardiac events, according to the largest study to address this question.
Biologics were associated with a reduced risk for both major adverse cardiac events (MACE) and venous thromboembolism (VTE) relative to no biologics. Small molecule therapies, such as